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INTRODUCTION 
Sustained-release theophylline products have improved drug therapy 
for many patients with asthma and chronic obstructive pulmonary disease 
(COPD). The use of these products can prolong the dosing interval, 
1 2 improve control of symptoms, and increase patient compliance. 
Differences in the extent of absorption and fluctuation of serum 
concentrations have been characterized for various sustained-release 
3 
theophylline formulations. As a result, the dose and dosing interval 
should be carefully re-evaluated when changing from the use of one 
formulation to another. 
® 
Constant-T (Cord Laboratories, Broomfield, Colorado) has replaced 
® 
Theo-Dur (Key Pharmaceuticals, Miami, Florida) as the 
sustained-release theophylline product on the hospital formulary at the 
Veterans Administration Medical Center (VAMC) in Salt Lake City, Utah. 
Subsequently, there have been anecdotal reports of subtherapeutic and 
toxic serum concentrations resulting when elderly VAMC patients have 
® ® 
been converted from Theo-Dur to Constant-T at equivalent doses. This 
prompted an inquiry into the bioavailability of these two slow-release 
tablets. To date, there have been no published studies which have 
® ® 
compared the bioavailability of Constant-T and Theo-Dur . An 
unpublished, comparative, bioavailability study has been conducted with 
* 
healthy male subjects ranging in age from 20 to 26 years. In this 
study, a statistically significant difference in the bioavailability of ® ® 
Constant-T and Theo-Dur was not revealed. Also, unpublished bioavail-
® 
ability studies of Constant-T have been performed with healthy male 
* 
Straughn AB. Sustained-released theophylline preparations (study 
XIV). Data on file, Key Pharmaceuticals, 1981. 
2 
subjects. In the summary of a single dose study, the difference in 
® 
bioavailability between Constant-T and a reference product was statis-
tically insignificant. 
® 
There are no studies describing the bioavailability of Constant-T 
in patients with COPD or in elderly adults. Moreover, it is unclear 
whether or not pharmacokinetic data from young healthy adults may be 
extrapolated to elderly patients because of possible differences in 
drug absorption and clearance which could alter bioavailability. 
Differences in the gastrointestinal tract, such as elevated 
gastric pH and reduced gastrointestinal blood flow, have been described 
4 
in cross-sectional studies of young and elderly adults. 
Theoretically, elevated gastric pH could decrease the rate and extent 
of absorption of a weak acid such as theophylline (pKa 8.77). Reduced 
gastrointestinal blood flow could also decrease drug absorption. No 
data exist, however, to support an assertion that the absorption of 
4-7 
theophylline or other drugs is decreased in the elderly. Clearance 
and bioavailability (area under the serum concentration-time curve) are 
inversely related. As data on age-related changes in theophylline 
8—13 
clearance are conflicting, the relationship between the 
bioavailability of theophylline in young adults and in elderly adults 
is unknown. 
® 
Therefore, a comparative bioavailability study of Constant-T and 
® 
Theo-Dur should be performed with elderly patients in order to 
identify possible bioavailability differences between these products in 
such patients. 
+ ® 




The objectives of this study were as follows: 
1) to compare the bioavailability of Constant-T® and Theo-Dur® 
in geriatric patients with COPD 
2) to compare the peak to trough differences in serum 
, ® ® 
theophylline concentration from Constant-T and Theo-Dur in 
geriatric patients with COPD. 
METHODS 
The study was approved by the Institutional Review Board and the 
Therapeutic Agents and Pharmacy Review Committee of the medical center. 
All subjects enrolled in the study agreed to participate as subjects 
and gave written informed consent. 
Subject Selection 
Patients evaluated as potential study subjects constituted the 
clientele of the VAMC pulmonary clinic and VAMC geriatric clinic during 
the first six months of 1984. Patients admitted to the VAMC medicine 
units during that period were also reviewed. Patients were enrolled in 
the study if the following criteria were met: age of 70 years or 
greater (required for admission to the Geriatric Evaluation and Treat-
ment Unit), stable COPD and stable cardiovascular function (as deter-
mined by physical examination and physician's assessment), and use of 
® 
Constant-T twice daily prior to the study. 
The presence of the following disease states noted on examination 
or by history constituted criteria for exclusion from the study: cor 
pulmonale, unstable congestive heart failure, fever, respiratory tract 
infection, hepatitis, cirrhosis, and acute exacerbation of COPD. Also 
8 
® 
Dur . This may be compared to coefficients of variation in other 
® 
studies of Theo-Dur . Straughn summarized a single dose, three-way, 
® ® 
crossover study of Theo-Dur , Constant-T , and an immediate-release 
® 
theophylline tablet (Slo-Phyllin , Dooner Laboratories, Haverhill, 
Massachusetts). There were six, healthy, nonsmoking, male adults (mean 
age, 23.8 years) in the study. The coefficients of variation of the 
mean AUC's for Theo-Dur®, Constant-T®, and Slo-Phyllin® were 29%, 38%, 
and 24%, respectively. Dasta et al compared the AUC's for Theo-Dur® 
and an uncoated aminophylline tablet in ten patients with COPD (mean 
age 39.8 years).^ Calculated from the reported data, the coefficient 
® 
of variation for the mean AUC for Theo-Dur was 41% and for aminophyl-
line was 50%. These data represent the variation in AUC's resulting 
from non-identical subjects. While the sample in the present study was 
homogeneous with respect to age, the presence of COPD, and the presence 
of CHF, AUC's varied among the subjects and reflected the net effects 
of differences in normal physiology and in pathologic processes. 
Associated with changes in theophylline bioavailability are 
diseases (e.g., CHF, cirrhosis), medications (e.g., cimetidine, propran-
olol), age (e.g., infancy, adolescence), dietary composition (e.g., 
high protein-low carbohydrate intake, low protein-high carbohydrate 
3 
intake), and cigarette use. If intersubject variability is related to 
heterogeneity with respect to these characteristics that are associated 
with changes in theophylline bioavailability, then intersubject varia-
bility may be minimized with subject selection that excludes or matches 
for these characteristics. Clinical criteria for the inclusion and 
exclusion of subjects were applied in the present study in an attempt 
to minimize intersubject variability. Stable CHF (four subjects) and 
cigarette use (one subject) are identifiable characteristics of sub-
jects in the present study which may have contributed to intersubject 
variability and which may be reflected in the coefficients of variation 
of the mean AUC's (Table 7). 
Intrasubject variability in theophylline pharmacokinetics has been 
17 18 
recently observed. ' Dederich et al examined the plasma theophyl-
® ® 
line concentrations from Theo-Dur and Slo-Phyllin Gyrocaps in eight , 
healthy, non-smoking adults (age range 20-27 years).^ Subjects 
® 
received four single doses of theophylline, two of Theo-Dur and two of 
® 
Slo-Phyllin Gyrocaps , and the single dose plasma concentration-time 
curves were analyzed. Intra-subject per cent change in AUC was calcu-
lated as a percentage of the highest AUC observed. The range of 
intrasubject per cent change in AUC was 0 to 23 for Slo-Phyllin Gyro-
® ® 
caps and 4 to 21 for Theo-Dur . 
Upton et al described intrasubject variability in terminal dispo-
18 
sition rate constants for theophylline elimination. Fluctuations of 
60% were observed. Fluctuations of 30% or greater were common, occur-
ring within as few as three or four days. As AUC and terminal dispo-
sition rate constants are inversely related (when volume of distribu-
tion is constant), intrasubject fluctuations in the terminal disposi-
tion rate constant for theophylline may be observed as fluctuations in 
AUC that occur in the opposite direction. 
In the absence of a test-retest study design, possible intrasub-
ject variability in the present study may not be documented. The 
conditions under which intrasubject variability occurs in normal 
subjects are not known. Therefore, the assumption that theophylline 
clearance for any given subject is constant during a crossover study 
10 
may be questioned. As a result, crossover studies of small sample 
size, such as the present study, possibly may be prone to considerable 
error from intrasubject variability. 
Area under the serum concentration-time curve is directly related 
to the amount of theophylline reaching systemic circulation. This may 
be influenced by variability in tablet content of theophylline. The 
average theophylline content, corresponding to the lot numbers of ® 
Theo-Dur used in the present study, was 199 mg per tablet for the 200 
mg tablets and 297 mg per tablet for the 300 mg tablet.^ Comparable 
® 
information for Constant-T was not available for this report. With 
® 
respect to Theo-Dur , the effect of tablet content variability on AUC 
in the present study appears to have been relatively minor. 
TM 
The TDx assay used to determine serum theophylline concentra-
tions in the present study is a fluorescence polarization immunoassay. 
TM 
For theophylline, Abbott Laboratories report the TDx assay to have a 
lower limit of detection of 0.3 mcg/ml and coefficients of variation of 
1.5%, 2.3%, and 3.0% at 26 mcg/ml, 12 mcg/ml, and 7 mcg/ml, respec-
19 TM 
tively. The TDx assay will not calculate serum theophylline 
concentrations above 40 mcg/ml; serum theophylline concentrations above 
40 mcg/ml are quantified using dilution techniques. Elevated hemoglo-
bin or triglyceride levels do not significantly affect the assay for 
theophylline. With elevated bilirubin, theophylline concentrations 
19 
show a mild positive bias. In the present study, serum theophylline 
concentrations were well within the limits of detection. Concentra-
tions ranged from 5.77 mcg/ml to 20.80 mcg/ml. Bias due to bilirubin 
in serum samples was minimal since the bilirubin levels in all subjects 
were within normal physiologic limits. The variability imparted to the 
^Data on file, Key Pharmaceuticals. 
11 
TM 
present study by the TDx assay was probably small. It should be 
TM 
noted that the range of variability introduced by the TDx assay at a 
specific serum theophylline concentration is constant and may be 
described by the coefficient of variation. As serum theophylline 
concentrations during any sampling interval were fairly close in 
magnitude, variability (described by a coefficient of variation of less 
than 6%) may be expected to be constant and randomly distributed among 
concentrations during that sampling interval. 
20 21 
Error in data analysis occurs with the estimation of AUC. ' 
The error may be minimized with the appropriate application of algo-
rithms. The linear trapezoidal method and the logarithmic trapezoidal 
method are often used to estimate AUC. With the linear trapezoidal 
method, linear interpolation between data points occurs. This method 
will underestimate area under a convex curve and overestimate area 
under a concave curve. With the logarithmic trapezoidal method, 
logarithmic decay between data points is assumed. Large errors may 
occur when this method is used with ascending data, near peak data, or 
20 
with sharply descending data. This method cannot be used when a y 
value is zero or when the y values of consecutive data points are 
equal. Generally, the linear trapezoidal method should be used with 
prepeak and plateau data, and the logarithmic trapezoidal method should 
21 
be used with postpeak data. In the present study, AUC was estimated 
with the linear trapezoidal method. As serum theophylline concentra-
tions were measured at steady state for 12 hours following administra-
tion of a slow-release tablet, the data was largely prepeak and plateau 
data. In a few sampling periods, the logarithmic trapezoidal rule 
could have been applied; however, the AUC estimations from the combined 
12 
use of the linear and logarithmic trapezoidal method s were the same as 
estimations using the linear trapezoidal method alone. 
Based on the AUC data and variability generated in the present 
study, sample size needed to fulfill the study objectives may be 
estimated. A sample of approximately 12 elderly patients with COPD 
probably would be required, using a matched pair t test (two-tailed, 
p < 0.05), to detect a 20% difference in the bioavailability of Con-
® ® 
stant-T and Theo-Dur if such a difference existed (Appendix 1). 
The objectives of the present study have been fulfilled; however, 
the question of a potential difference in the bioavailability of ® ® 
Constant-T and Theo-Dur in geriatric patients remains unanswered. 
Hendeles and Weinberger reviewed data on extent of absorption and 
predicted fluctuations in serum concentrations for 13 brands of sustain-
3 
ed-release theophylline. Extent of absorption generally varied 
® 
between 86% and 103%; Constant-T was listed as being 76% absorbed. 
Serum fluctuations were predicted for eight and twelve hour dosing 
intervals with theophylline half-lives of 3.7 hours and 8.2 hours. 
With several products, predicted fluctuations corresponded to subthera-
peutic and toxic serum concentrations. The extent of absorption and 
® 
predicted serum fluctuations for Constant-T appear to be based on two 
unpublished bioavailability reports, one on file with Key Pharmaceuti-
cals and one on file with Geigy Pharmaceuticals. The former report was 
submitted by Straughn and has been discussed above. Compared to the 
® ® reference product (Slo-Phyllin ) and based on total AUC, Theo-Dur and ® 
Constant-T were statistically distinguishable from the reference 
product but were statistically indistinguishable from each other. 
® 
Based on AUC from t=0 hours to t=30 hours, Theo-Dur was 86% bioavail-
13 
® 
able, and Constant-T was 74% bioavailable. These figures are statis-
tically different. The latter report was under the direction of Meyer 
and consisted of a single dose and a multiple dose study. Summaries of 
these studies, provided by Geigy Pharmaceuticals, lack the raw data 
needed for discussion here. Hendeles and Weinberger referred to these 
studies as showing 90% and 92% bioavailability for the two dosage forms 
studied and "larger inter- and intrapatient variability." Neither the 
Straughn report nor the Meyer report studied elderly patients or 
patients with COPD. Possible differences in drug absorption and 
clearance occur with aging and may limit the extrapolation of these 
® ® 
reports to elderly patients receiving Constant-T and Theo-Dur . 
Bender reviewed studies dealing with intestinal absorption and 
4 
aging. In the elderly, basal and maximal acid output is decreased. 
Splanchnic blood flow is markedly reduced. These changes could affect 
the solubility and delay the absorption of certain drugs, thus decreas-
ing bioavailability. Decreased number of active cells in the intestin-
al absorptive surface and changes in active transport processes possi-
bly occur with aging. However, no data exist to demonstrate that drug 
absorption is altered in the elderly. Studies of paracetamol, sulpha-
methizole, phenylbutazone, amylobarbitone, propranolol, and pethidine 
revealed no changes in absorption of these drugs in elderly patients 
compared to younger patients 
Bioavailability may be derived by the ratio of dose to clearance, 
hence characterization of theophylline clearance in the elderly addi-
tionally describes theophylline bioavailability in the elderly. Trends 
in theophylline clearance in the elderly are obscured by conflicting 
data. Fox et al reported greater rates of theophylline clearance in 
14 
11 9 elderly patients than in younger patients. Bauer and Blouin, Cusack 
10 13 12 et al, Powell et al, and Wiffen et al found no age-related 
changes in theophylline clearance. Antal et al characterized single 
g 
dose theophylline kinetics in elderly and young adults. There were no 
differences in volume of distribution or overall plasma clearance based 
on total plasma theophylline. A 37% decrease in volume of distribution 
(p < 0.005) and a 30% decrease in overall plasma clearance (p < 0.02) 
in elderly subjects were noted when calculations were based on unbound 
plasma theophylline. These findings suggest that AUC based on total 
theophylline concentrations conceal changes in theophylline disposition 
that may occur with aging. Also, these findings serve to limit the 
validity of extrapolating to elderly patients the results of bioavail-
ability studies performed with young adults, thus supporting the need 
for the present study. 
CONCLUSION 
Data do not exist in published studies to satisfy concerns raised 
® 
when VAMC patients in Salt Lake City were converted from Theo-Dur to 
® 
Constant-T . The objectives of the present study were to compare the 
® 
bioavailability and peak to trough differences with Constant-T and ® 
Theo-Dur in elderly patients with COPD. Performed with five subjects, 
preliminary data in the present study uncovered no major differences in 
bioavailability or peak to trough differences. The present study may 
need to be completed with a sample of approximately 12 patients in 
order to detect potential differences of 20% or greater in the bioavail-





AGE, PERTINENT DIAGNOSES AND HISTORY, AND 
THEOPHYLLINE DOSES OF SUBJECTS 
* + 
Subject No. Age (yrs) Diagnosis & History Theophylline Dose 
1 83 COPD, CHF 400 mg 
2 75 COPD, CHF, SMOKER 300 mg 
3 73 COPD 200 mg 
4 75 COPD, CHF 300 mg 
5 87 COPD, CHF 300 mg 
COPD - stable chronic obstructive pulmonary disease 
CHF - stable congestive heart failure 
SMOKER - current cigarette use 
theophylline doses were administered orally every twelve hours 
TABLE 2 
SERUM THEOPHYLLINE CONCENTRATIONS 
FOR SUBJECT NO. 1 
® ® Sample Time (hours) Constant-T (mcg/ml) Theo-Dur (mcg/ml) 
0 9.96 10.35 
0.5 * 9.14 10.92 
1 11.51+ 11.50 
2 11.26+ 10.85 
3 11.65 11.42 
4 14.43 11.98 
6 16.66 9.57 
8 13.87 5.77 
10 12.03 6.17 
12 9.68 5.82 
+Sample time was 0.583 hours 
^Sample time was 1.083 hours 
.Sample time was 2.083 hours 
Sample time was 8.417 hours 
18 
TABLE 3 
SERUM THEOPHYLLINE CONCENTRATIONS 
FOR SUBJECT NO. 2 
Sample Time (hours) Constant-T® (mcg/ml) Theo-Dur® (mcg/ml) 
0 8.25 8.30 
0.5 6.58 9.28 
1 6.87 9.54 
2 7.47 8.76 
3 7.78 9.69 
4 10.20 9.86 
6 11.12 11.82 
8 9.21 11.27 
10 7.41 9.61 
12 6.14 7.83 
19 
TABLE 4 
SERUM THEOPHYLLINE CONCENTRATIONS 
FOR SUBJECT NO. 3 
Sample Time (hours) Constant-T® (mcg/ml) Theo-Dur® (mcg/ml) 
0 9.31 8.07 
0.5 10.16 8.39 
1 10.71 8.81 
2 12.15 8.83 
3 12.47 8.53 
4 12.83 9.53 
6 12.18 9.37 
8 11.18 9.35 
10 10.70 8.52 
12 9.83 7.74 
20 
TABLE 5 
SERUM THEOPHYLLINE CONCENTRATIONS 
FOR SUBJECT NO. 4 
Sample Time (hours) Constant-T® (mcg/ml) Theo-Dur® (mcg/ml) 
0 14.16 18.39 
0.5 13.60 17.66 
1 13.91 18.03 
2 14.41 18.38 
3 14.95 18.32 
4 14.68 18.56 
6 14.68 19.73 
8 14.24 20.80 
10 11.83 19.08 
12 12.41 17.42 
TABLE 
SERUM THEOPHYLLINE CONCENTRATIONS 
FOR SUBJECT NO. 5 
Sample Time (hours) Constant-T® (mcg/ml) Theo-Dur® (mcg/ml) 
0 7.73 8.95 
0.5 8.14 8.75 
1 9.34 9.19 
2 9.05 9.66 
3 9.27 9.82 
4 9.02 9.26 
6 8.79 9.34 
8 8.18 9.23 
10 10.66 8.26 
12 9.45 7.57 
22 
TABLE 7 
AREA UNDER THE SERUM CONCENTRATION-
TIME CURVE FOR CONSTANT-T® AND THEO-DUR® 
® ® Subject No. Constant-T (meg- hr/ml) Theo-Dur (meg- hr/ml) 
1 116 80 
2 103 120 
3 * 206 160 
4 166 228 
5 110 108 
Mean 140 139 
(CV ) (32%) (41%) 
* 
formalized to 300 mg 
Coefficient of variation 
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Sample size may be approximated from the equation for the 
student's t statistic (Equation 1). 
d - 0 
V i = sd (1> 
where t_ is the student's statistic 
d is the average of sample differences 
s^ is the standard error of sample differences and 
n is the number of pairs of data (i.e., sample size). 
To be used in sample size estimations, Equation 1 is solved for n. 
k2 
(2) 
The sample size estimation in the present study was performed with 
the following assumptions: 
1) The null hypothesis states there is go difference ^n the 
population mean AUC's for Constant-T and Theo-Dur . 
H : AUC = AUC . o ct td 
where H stands for null hypothesis 
A0C . stands for the population mean AUC for Constant-T & 
AUC^ stands for the population mean AUC for Theo-Dur . 
2) The alternate hypothesis states^ there is a difference in the 
population mean AUC's for Constant-T and Theo-Dur . 
H : AUC * AUC , a ct td 
where H^ stands for alternate hypothesis. 
® 
3) The sampling distributions of the AUC's for Constant-T and 
Theo-Dur have similar variance. 
4) The significance level is 0.05. 
5) The AUC data (Table 7) approximate the population mean and 
variance. 
6) A difference in mean AUC's of 20% or greater should be 
detected if such a difference exists. 
32 
Using Equation 2, sample size (n) may be approximated by iteration 
with the t value initially chosen from an estimation of degrees of 
freedom (df). In subsequent calculations, df is determined from the 
previously calculated n (df = n - 1), and the corresponding t value is 
re-entered into the equation. 
Determined from the AUC data (Table 7), d" equals 28 (20% of 140 
meg • hr/ml), and s^ equals 43.4. Equation 2 is eventually solved for n 
as follows: 
Hence using a matched pair t test (two-tailed, p < 0.05), the 
present study probably requires approximately 12 subjects to detect a 
n = 11.6 
20% difference in the bioavailability of Constant-T and Theo-Dur , if ® 




CONSENT AND AGREEMENT TO PARTICIPATE AS AN 
EXPERIMENTAL SUBJECT IN CLINICAL RESEARCH 
INFORMATION ABOUT BIOAVAILABILITY OF CONSTANT-T® AND THEO-DUR®, 
TWO SUSTAINED-RELEASED THEOPHYLLINE PRODUCTS, IN GERIATRIC PATIENTS 
You have been taking a brand of sustained-released theophylline to 
improve your breathing. The purpose of this study is to compare the 
absorption and blood levels of 2 different brands of sustained-release 
theophylline, Constant-T and Theo-Dur . 
If you decide to participate in the study, you will undergo the proce-
dure outlined below. 
1) This study will take six days to complete. During the first three 
dgys, you will@receive one of the two study medications (Constant-
T or Theo-Dur ), and during the last thr^e days you wil^ receive 
the other study medication (Constant-T or Theo-Dur ). The 
medication will be given to you twice daily at the same dose of 
theophylline you are taking now. There is a small chance you will 
have side effects, such as nausea or nervousness, from the medica-
tion. Also, there is a small chance you will develop symptoms of 
your breathing problem. Your medication will be changed by a 
physician if any of these effects occur. 
2) On the third and sixth days of the study, a small blood catheter 
will be inserted into a vein on one arm for about 12 hours. The 
catheter will allow blood samples to be obtained without having a 
needle stick each time. The catheter may produce a small amount 
of discomfort and swelling at the site of insertion (as can a 
needle stick). 
3) A total of 20 blood samples will be obtained during the study. 
The amount of blood in each sample is equal to about lh teaspoon-
fuls (or 6 milliliters). This will not cause you any harm. 
4) You will receive your regular hospital diet while in the study 
except for 12 hours on the third and sixth days when you will 
fast. You will be able to drink water during the fast, but food 
will not be allowed. 
The major benefit from this study wiiy. be the comparison of the absorp-
tion and blood levels of Constant-T and Theo-Dur . The benefits to 
you include careful evaluation of@your blood levels of theophylline 
that occur when you take Constant-T and Theo-Dur and constant medical 
supervision during the study at no cost to you. You may ask questions 
about the study at any time by calling Mr. Tony Ranno at 581-5941(days) 
or 583-3409(nights), Dr. Susan Stephenson at 582-1565 (Ext. 1018), Dr. 
Martin Higbee at 581-5941, or Dr. Jim Wood at 582-1565 (Ext. 1018). 
35 
The above clinical research project in which I have volunteered to 
participate as an experimental subject has been fully explained to me, 
and I understand the purpose of the project and the potential benefits 
to be derived by me. I have also had the procedure fully explained to 
me, and I fully understand the procedure that will be carried out on my 
person and the potential risks and discomforts that are involved. I 
have had ample opportunity to ask questions concerning the above 
procedures. I understand that I am free to withdraw my participation 
in the study at any time without prejudice. I agree that the data from 
these experiments may be used for medical and scientific purposes, 
including publication, with the understanding that my identity will not 
be revealed unless I expressly consent to it. 
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